United States · FDA National Drug Code directory
theophylline
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 60219-2045_a823c8c2-f712-4ea7-b3ca-8b5452743893
- Product NDC
- 60219-2045
- Form
- TABLET, EXTENDED RELEASE
- Composition / generic term
- theophylline
- Labeler
- Amneal Pharmaceuticals NY LLC
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20230327
- Source listing expiry
- 20271231
Source-listed ingredients
- THEOPHYLLINE ANHYDROUS — 300 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 100 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (60219-2045-1) · 60219-2045-1
- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (60219-2045-3) · 60219-2045-3
- 500 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (60219-2045-5) · 60219-2045-5
- 1000 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (60219-2045-7) · 60219-2045-7
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →